Clinical features of patients with AML
. | Data . |
|---|---|
| No. of patients | 10 |
| Median age, y (range) | 63 (46-81) |
| No. of men (%) | 6 (60) |
| AML features, no. | |
| De novo | 8 |
| Arising from myelodysplasia | 2 |
| Arising following treatment | 0 |
| Status at time of treatment, no. | |
| Initial therapy | 2 |
| Primary refractory disease | 2 |
| Relapsed disease, less than 12 mo | 4 |
| Relapsed disease, more than 12 mo | 2 |
| Relapse after autologous transplantation | 2 |
| Relapse after allogeneic transplantation | 1 |
| Median WBC, × 109/L (range) | 2.2 (0.8-16.6) |
| Median Hgb, g/dL, (range) | 9.9 (8.3-12.7) |
| Median platelets, × 109/L (range) | 61 (10-187) |
| Median ECOG performance status (range) | 1 (0-2) |
| On hydroxyurea prior to treatment, no. | 2 |
| Active problem requiring hospitalization, no. | 1 |
| CALGB cytogenetic classification, no. | |
| Low risk | 0 |
| Intermediate risk | 8 |
| High risk | 2 |
. | Data . |
|---|---|
| No. of patients | 10 |
| Median age, y (range) | 63 (46-81) |
| No. of men (%) | 6 (60) |
| AML features, no. | |
| De novo | 8 |
| Arising from myelodysplasia | 2 |
| Arising following treatment | 0 |
| Status at time of treatment, no. | |
| Initial therapy | 2 |
| Primary refractory disease | 2 |
| Relapsed disease, less than 12 mo | 4 |
| Relapsed disease, more than 12 mo | 2 |
| Relapse after autologous transplantation | 2 |
| Relapse after allogeneic transplantation | 1 |
| Median WBC, × 109/L (range) | 2.2 (0.8-16.6) |
| Median Hgb, g/dL, (range) | 9.9 (8.3-12.7) |
| Median platelets, × 109/L (range) | 61 (10-187) |
| Median ECOG performance status (range) | 1 (0-2) |
| On hydroxyurea prior to treatment, no. | 2 |
| Active problem requiring hospitalization, no. | 1 |
| CALGB cytogenetic classification, no. | |
| Low risk | 0 |
| Intermediate risk | 8 |
| High risk | 2 |